Technical Analysis for GLSI - Greenwich LifeSciences, Inc.

Grade Last Price % Change Price Change
grade F 3.85 -4.47% -0.18
GLSI closed down 4.47 percent on Wednesday, October 28, 2020, on 30 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical GLSI trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -4.47%
Hot IPO Pullback Bullish Swing Setup -4.47%
Narrow Range Bar Range Contraction -4.47%
Older End-of-Day Gignals for GLSI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 5 days ago
Down 2 % 5 days ago
Down 1% 5 days ago
New 52 Week Low 5 days ago
Fell Below Previous Day's Low 5 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Medicine Biopharmaceutical Health Clinical Medicine Surgery Immunotherapy Cancer Treatments Clinical Trial Breast Cancer Her2/Neu

Is GLSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.75
52 Week Low 3.82
Average Volume 13,858
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 4.45
10-Day Moving Average 4.32
Average True Range 0.40
ADX 0.0
+DI 11.73
-DI 19.64
Chandelier Exit (Long, 3 ATRs ) 4.13
Chandelier Exit (Short, 3 ATRs ) 5.01
Upper Bollinger Band 5.07
Lower Bollinger Band 3.84
Percent B (%b) 0.01
BandWidth 27.66
MACD Line -0.21
MACD Signal Line -0.10
MACD Histogram -0.1135
Fundamentals Value
Market Cap 45.99 Million
Num Shares 11.9 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.12
Resistance 3 (R3) 4.14 4.07 4.08
Resistance 2 (R2) 4.07 4.00 4.06 4.06
Resistance 1 (R1) 3.96 3.96 3.93 3.94 4.04
Pivot Point 3.89 3.89 3.87 3.88 3.89
Support 1 (S1) 3.78 3.82 3.75 3.76 3.66
Support 2 (S2) 3.71 3.78 3.70 3.64
Support 3 (S3) 3.60 3.71 3.63
Support 4 (S4) 3.58